Impact of Glutathione-S-Transferases (GST) Polymorphisms and Hypermethylation of Relevant Genes on Risk of Prostate Cancer Biochemical Recurrence: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Chen, Rui ^a   Ren, Shancheng ^a   Meng, Tong ^b   Aguilar, Josephine ^c   Sun, Yinghao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GLUTATHIONE TRANSFERASE;

ARTICLE; CANCER RECURRENCE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; COHORT ANALYSIS; DNA METHYLATION; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; DNA METHYLATION; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PUBLICATION BIAS; RISK FACTORS;

EID: 84884526271     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074775     Document Type: Article

References (37)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328.
3. Andriole GL, Crawford ED, Grubb RL, (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104: 125-132.
4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, et al. (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169: 517-523.
5. Busch J, Stephan C, Herold A, Erber B, Kempkensteffen C, et al. (2012) Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience. BJU Int 110: E985-990.
6. Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, et al. (2008) A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 112: 1254-1263.
7. Freedland SJ, Sutter ME, Dorey F, Aronson WJ, (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61: 365-369.
8. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, et al. (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433-439.
9. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597.
10. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, et al. (2006) Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98: 715-717.
11. Chun FK, Karakiewicz PI, Huland H, Graefen M, (2007) Role of nomograms for prostate cancer in 2007. World J Urol 25: 131-142.
12. Hayes JD, Flanagan JU, Jowsey IR, (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45: 51-88.
13. Wei B, Xu Z, Zhou Y, Ruan J, Cheng H, et al. (2012) Association of GSTM1 null allele with prostate cancer risk: evidence from 36 case-control studies. PLoS One 7: e46982.
14. Wiklund FE, Adami HO, Zheng SL, Stattin P, Isaacs WB, et al. (2009) Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev 18: 1659-1662.
15. Cotignola J, Leonardi DB, Shahabi A, Acuna AD, Stern MC, et al. (2012) Glutathione-S-transferase (GST) polymorphisms are associated with relapse after radical prostatectomy. Prostate Cancer Prostatic Dis.
16. Nock NL, Bock C, Neslund-Dudas C, Beebe-Dimmer J, Rundle A, et al. (2009) Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity. Cancer Causes Control 20: 1915-1926.
17. Agalliu I, Lin DW, Salinas CA, Feng Z, Stanford JL, (2006) Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis. Prostate 66: 1535-1541.
18. Dluzniewski PJ, Wang MH, Zheng SL, De Marzo AM, Drake CG, et al. (2012) Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 21: 1774-1782.
19. Phe V, Cussenot O, Roupret M, (2010) Methylated genes as potential biomarkers in prostate cancer. BJU Int 105: 1364-1370.
20. Chiam K, Ricciardelli C, Bianco-Miotto T (2012) Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett.
21. Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, et al. (2012) Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18: 2882-2895.
22. Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, et al. (2011) Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 129: 2454-2462.
23. Ellinger J, Haan K, Heukamp LC, Kahl P, Buttner R, et al. (2008) CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68: 42-49.
24. Ellinger J, Bastian PJ, Jurgan T, Biermann K, Kahl P, et al. (2008) CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71: 161-167.
25. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, et al. (2005) Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11: 4037-4043.
26. Woodson K, O'Reilly KJ, Ward DE, Walter J, Hanson J, et al. (2006) CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 1: 183-186.
27. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, et al. (2005) Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clinical Cancer Research 11: 8321-8325.
28. Phe V, Cussenot O, Roupret M, (2010) Methylated genes as potential biomarkers in prostate cancer. BJU International 105: 1364-1370.
29. Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Muller SC, et al. (2007) Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 51: 665-674; discussion 674.
30. Esteller M, Corn PG, Baylin SB, Herman JG, (2001) A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229.
31. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, et al. (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64: 1975-1986.
32. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
33. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
34. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
35. Gsur A, Haidinger G, Hinteregger S, Bernhofer G, Schatzl G, et al. (2001) Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer 95: 152-155.
36. Trock BJ, Brotzman MJ, Mangold LA, Bigley JW, Epstein JI, et al. (2012) Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 110: 56-62.
37. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, et al. (2004) A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10: 8472-8478.